ArticleiScience2026
Pan-cancer 8q24 amplification predicts primary immunotherapy resistance and therapeutic vulnerabilities.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint blockade has transformed cancer therapy, yet most patients do not respond and reliable predictive biomarkers are lacking. Amplification of chromosomal region 8q24.21 is recurrent across cancer types, but its role in anti-tumor immunity is unknown. Through pan-cancer profiling of 10,809 tumor samples and validation in five independent immunotherapy cohorts (over 800 patients), we show that 8q24 amplification occurs in approximately 10% of human cancers and promises an immune-depleted microenvironment with reduced T cell infiltration and impaired antigen presentation. 8q24 amplification robustly predicted primary immunotherapy resistance and poor survival. A composite score integrating 8q24 status, tumor mutational burden, and PD-L1 expression effectively identified non-responders. Prognosis-driven and cell-line screening revealed 8q24-specific therapeutic vulnerabilities, providing a framework for targeted combination strategies in this genomically defined patient subset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.